Submissions from 2024
Safety and Tolerability of Atogepant for the Preventive Treatment of Migraine: A Post Hoc Analysis of Pooled Data from Four Clinical Trials, Paul Rizzoli, Michael Marmura, Jennifer Robblee, Jennifer McVige, Sara Sacco, Stephanie Nahas, Jessica Ailani, Rosa De Abreu Ferreira, Julia Ma, Jonathan Smith, Brett Dabruzzo, and Messoud Ashina
Real-World Effectiveness of Add-Onfremanezumab in Patients Receiving OnabotulinumtoxinA for the Prevention of Chronic Migraine in a US Tertiary Headache Center: A Retrospective Chart Review Study, Hsiangkuo Yuan, Fred Cohen, Maurice T. Driessen, Lynda J. Krasenbaum, Mario Ortega, Mary Hopkins, and Michael J. Marmura
Submissions from 2023
A Novel Virtual-Based Comprehensive Clinical Approach to Headache Care, Thomas Berk, Stephen Silberstein, and Peter McAllister
Persistence to Anti-CGRP Monoclonal Antibodies and onabotulinumtoxinA Among Patients With Migraine: A Retrospective Cohort Study, Larry Charleston, Brian Talon, Christine Sullivan, Carlton Anderson, Steven Kymes, Stephane A. Regnier, Seema Soni-Brahmbhatt, and Stephanie J. Nahas
Drug-Free Noninvasive Thermal Nerve Block: Validation of Sham Devices, Michael Fishman, Ahish Chitneni, Alaa Abd-Elsayed, Samuel Grodofsky, Ashley Scherer, Brendan Schetzner, Malvina Klusek, Stephen Popielarski, Stephen Meloni, Steven Falowski, Philip Kim, Konstantin Slavin, and Stephen Silberstein
Novel Therapeutic Targets for Migraine, Areeba Nisar, Zubair Ahmed, and Hsiangkuo Yuan
Treatment of Chronic Migraine with Botox (Onabotulinumtoxina): Development, Insights, and Impact, Catherine C. Turkel, Sheena Aurora, Hans-Christoph Diener, David W. Dodick, Richard B. Lipton, Stephen D. Silberstein, and Mitchell F. Brin
Submissions from 2022
The Importance of an Early Onset of Migraine Preventive Disease Control: A Roundtable Discussion, Christopher Gottschalk, Anirban Basu, Andrew Blumenfeld, Bradley Torphy, Michael J. Marmura, Jelena M. Pavlovic, Paula K. Dumas, Nim Lalvani, and Dawn C. Buse
Submissions from 2020
Treatment patterns of patients diagnosed with major headache disorders: A retrospective claims analysis, David Kudrow, Sagar Munjal, Leah Bensimon, Tasneem Lokhandwala, Binglin Yue, Anna D’Souza Coutinho, and Stephen D. Silberstein
Submissions from 2014
Safety of topiramate for treating migraines., Michael J. Marmura
Letter to Alliance for Headache Disorders Advocacy, William B. Young, MD
Submissions from 2012
Increased variability of motor cortical excitability to transcranial magnetic stimulation in migraine: a new clue to an old enigma., Adriana B Conforto, Mariana S Moraes, Edson Amaro, William B Young, Lais A Lois, André L Gonçalves, and Mario F P Peres
Onabotulinumtoxin A in the Treatment of Migraine Headache, Carrie O. Dougherty, MD and Stephen Silberstein, MD
Metabolic syndrome and migraine., Amit Sachdev and Michael J Marmura
Submissions from 2010
A new frontier for headache., Stephen Silberstein
Submissions from 2009
Early and Late Treatment of Migraine with DHE NS (Migranal®), Meryl Latsko, MD, MPH and Stephen D. Silberstein, MD
Frovatriptan as Preemptive Treatment for Fasting-Induced Migraine, Meryl Latsko, MD, MPH and Stephen D. Silberstein, MD
Dynamic mechanical (brush) allodynia in cluster headache: a prevalence study in a tertiary headache clinic., Michael J Marmura, Muhammad Abbas, and Avi Ashkenazi
Submissions from 2007
Cephalalgiaphobia: a possible specific phobia of illness., Mario F P Peres, Juliane P P Mercante, Vera Z Guendler, Felipe Corchs, Marcio A Bernik, Eliova Zukerman, and Stephen Silberstein
Submissions from 2005
The Global Campaign (GC) to Reduce the Burden of Headache Worldwide. The International Team for Specialist Education (ITSE)., Paolo Martelletti, Redda T Haimanot, Miguel J A Láinez, Alan M Rapoport, K Ravishankar, Fumihiko Sakai, Stephen Silberstein, Maurice Vincent, and Timothy J Steiner
